Lopinavir ritonavir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
'''''For patient information, click <u>[[Lopinavir ritonavir (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Lopinavir ritonavir (patient information)|here]]'''''</u>. | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{MM}} | ||
==Overview== | ==Overview== | ||
Revision as of 03:20, 10 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
Antiretroviral
US Brand Names
KALETRA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Lopinavir is an antiviral drug. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.[1]
References
- ↑ "KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]". Text " accessdate" ignored (help)